Skip to main content
. 2020 Jan 23;9:1574. doi: 10.3389/fonc.2019.01574

Table 1.

Clinical characteristics of the breast cancer patients in this study.

HR+/HER2– (n = 410) No. (%)
Median age (min–max) (years) 47.3 (25.2–80.5)
Age (years)
   <50 241 (58.8%)
   ≥50 169 (41.2%)
Tumor size (cm)
   ≤ 2 183 (44.6%)
   2-5 204 (49.8%)
   >5 23 (5.6%)
Lymph node status
   Negative 203 (49.5%)
   Positive 207 (50.5%)
pN
   0 203 (49.5%)
   1 112 (27.3%)
   2 51 (12.4%)
   3 44 (10.7%)
Pathologic stage
   I 113 (27.6%)
   II 197 (48.0%)
   III 100 (24.4%)
Histologic grade
   1 77 (18.8%)
   2 199 (48.5%)
   3 123 (30%)
   Unknown 11 (2.7%)
Nuclear grade
   1 60 (14.6%)
   2 256 (62.4%)
   3 81 (19.8%)
   Unknown 13 (3.2%)
Hormone therapy
   No 21 (5.1%)
   Yes 379 (92.4%)
   Unknown 10 (2.4%)
Chemotherapy
   No 68 (16.6%)
   Yes 342 (83.4%)
   Unknown 0 (0.0%)
Radiotherapy
   No 162 (39.5%)
   Yes 247 (60.2%)
   Unknown 1 (0.2%)
NPI
   1 113 (27.6%)
   2 113 (27.6%)
   3 113 (27.6%)
   4 58 (14.1%)
   Unknown 13 (3.2%)

HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; pN, pathologic nodal status; NPI, Nottingham prognostic index.